COVID-19 Vaccines, Therapies Would Get Billion-Dollar Manufacturing Platform Under House Bill
House coronavirus legislation would boost domestic manufacturing capacity while further scrutinizing global supply chain.
You may also be interested in...
Whether major drug shortages result from the COVID-19 pandemic or not, manufacturers would face greater reporting requirements, especially for APIs.
Coronavirus hysteria sweeps up languishing drug shortage legislation; prospects for new reporting and risk management planning requirements improve.
The US government has a routine approach for negotiating single-seller/single-buyer contracts, but drug pricing politics and public fears of coronavirus will likely complicate any purchasing talks with a sponsor, should an effective vaccine or therapeutic emerge.